Peptide Research & Clinical Trials: How to Read the Science Behind the Headlines

Every week, a new headline claims a peptide "destroys belly fat" or is "the next Ozempic." Most of those headlines misrepresent the underlying research. Some have no research behind them at all.

This guide exists so you can cut through the noise yourself. We cover how peptide research actually works, which compounds are in clinical trials right now, how to evaluate study quality, and where the regulatory landscape stands in 2026.

Important: This content is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment guidance. Many compounds discussed here are investigational and not FDA-approved for human use. Always consult a qualified healthcare provider before making decisions about any medication or peptide protocol. See our full medical disclaimer.

Key takeaways:

• Peptide research follows the same preclinical-to-clinical pipeline as all drug development, but timelines and failure rates are often misrepresented online.
• Several next-generation weight loss peptides (retatrutide, survodutide, orforglipron, CagriSema) are in Phase 3 trials with strong data -- but none are approved yet.
• Not all research is equal. A randomized controlled trial in 2,000 people carries far more weight than an animal study or a Reddit anecdote.
• The FDA regulatory landscape for peptides changed significantly in 2024-2025, particularly around compounding pharmacies.
• Learning to evaluate research quality yourself is the single best defense against hype, misinformation, and wasted money.

---

How peptide research works

Drug development follows a structured path. Understanding that path tells you exactly how far along any peptide actually is -- and how much trust to put in its results.

Preclinical research

Before any compound reaches a human body in a formal trial, it goes through preclinical work. This includes:

• In vitro studies -- testing in cell cultures or tissue samples in a lab. These establish basic biological activity. "Peptide X activated GLP-1 receptors in cell culture" is a preclinical finding.
• Animal studies -- typically in mice or rats, sometimes primates. These test safety, dosing ranges, and preliminary efficacy. Many peptides that show dramatic results in mice never work the same way in humans.

Preclinical data is the starting point, not the finish line. When someone claims a peptide "has been shown to" do something based only on animal data, that claim is real but extremely preliminary. The jump from mouse to human is where most compounds fail.

Clinical trial phases

If preclinical data looks promising, a pharmaceutical company files an Investigational New Drug (IND) application with the FDA. If approved, human testing begins in phases:

Phase 1 -- Safety and dosing (20-100 participants)

The primary goal is safety, not efficacy. Researchers give small doses to healthy volunteers and gradually increase to find the maximum tolerated dose. They track side effects, how the body absorbs and clears the drug, and basic safety markers. Most Phase 1 trials last a few months.

Phase 1 does not tell you whether a drug works. It tells you whether it is safe enough to keep testing.

Phase 2 -- Efficacy signal and dose-finding (100-500 participants)

Now the compound is tested in people who actually have the condition it targets. Researchers test multiple doses against placebo to find which dose produces the best balance of efficacy and side effects. Phase 2 trials typically last 6-24 months.

This is where we start seeing real weight loss data, metabolic improvements, or other measurable outcomes. But the sample size is still relatively small, and these trials are often designed more for learning than for proving.

The retatrutide Phase 2 trial (PMID: 37351564) enrolled 338 participants and produced the 24.2% weight loss number that generated so many headlines. That is strong Phase 2 data -- but it has not yet been confirmed in the larger Phase 3 trials.

Phase 3 -- Confirmatory trials (1,000-10,000+ participants)

Phase 3 is the big one. Large, multicenter, randomized, controlled trials designed to confirm efficacy and monitor safety across a broader population. These trials often run 1-4 years and cost hundreds of millions of dollars.

This is the data the FDA primarily relies on for approval decisions. Semaglutide's STEP trial program, for example, enrolled over 10,000 participants across multiple Phase 3 studies before Wegovy received FDA approval for obesity (PMID: 33567185).

Phase 4 -- Post-market surveillance

After FDA approval, ongoing monitoring tracks long-term safety in the general population. This is where rare side effects that did not show up in trials sometimes emerge, since millions of people are now using the drug instead of thousands.

What the failure rate actually looks like

Roughly 90% of drugs that enter Phase 1 never reach FDA approval. Even compounds that clear Phase 2 still fail about 40-50% of the time in Phase 3. These are important numbers to keep in mind when someone tells you a peptide in early trials is "the future."

It might be. But statistically, most are not.

---

New weight loss peptides in development (2026)

The GLP-1 receptor agonist class transformed obesity treatment. Now, pharmaceutical companies are racing to develop next-generation compounds that produce even greater weight loss, fewer side effects, or more convenient dosing. Here is where the most promising candidates stand.

Retatrutide (Eli Lilly) -- triple agonist

Retatrutide is the first triple hormone receptor agonist to reach advanced clinical trials. It activates three receptors simultaneously: GLP-1, GIP, and glucagon.

The data so far:

• Phase 2 trial (PMID: 37351564): 338 participants with obesity. The highest dose (12 mg) produced 24.2% mean body weight loss at 48 weeks. More than 90% of participants lost at least 10% of their body weight.
• A sub-study showed dramatic reductions in liver fat -- up to 86% reduction in participants with metabolic dysfunction-associated steatotic liver disease (MASLD).
• Common side effects followed the GLP-1 pattern: nausea, diarrhea, vomiting, constipation. Mostly mild to moderate and concentrated in the dose-escalation period.

Current status: Multiple Phase 3 trials (TRIUMPH program) are underway. Eli Lilly has not announced an expected FDA submission date, but completion data for the Phase 3 obesity trials is projected for late 2025 through 2026. If results hold, an FDA application could come in late 2026 or 2027.

Bottom line: The Phase 2 data is the strongest weight loss result published for any single compound. But Phase 2 is not Phase 3. We will not know the real picture until the larger trials read out. See our retatrutide FDA approval timeline for the latest updates.

Survodutide (Boehringer Ingelheim) -- GLP-1 + glucagon dual agonist

Survodutide takes a different dual-agonist approach from tirzepatide. Instead of GLP-1 + GIP, it combines GLP-1 with glucagon receptor activation.

The data so far:

• Phase 2 trial (PMID: 38587239): 387 participants. The highest dose produced approximately 18.7% weight loss at 46 weeks.
• Survodutide has shown notable effects on liver fat reduction, which is relevant for MASLD/NASH. The SYNCHRONIZE-1 trial showed significant improvements in liver histology.
• The glucagon component may provide metabolic benefits beyond what GLP-1-only or GLP-1/GIP compounds offer, particularly for liver health and energy expenditure.

Current status: Phase 3 trials for both obesity and MASLD/NASH are ongoing. Boehringer Ingelheim is running the SYNCHRONIZE program for liver disease and the ACHIEVE program for obesity.

Bottom line: The liver fat data is what makes survodutide interesting beyond pure weight loss numbers. If Phase 3 confirms the liver benefits, it could carve out a distinct niche from tirzepatide and retatrutide.

Orforglipron (Eli Lilly) -- the oral option

Orforglipron is technically not a peptide. It is a small molecule that activates the GLP-1 receptor, designed to be taken as a daily pill instead of a weekly injection.

The data so far:

• Phase 2 trial (PMID: 37351563): 272 participants. The highest dose produced approximately 14.7% weight loss at 36 weeks.
• The weight loss trajectory had not plateaued at 36 weeks, suggesting longer treatment could produce greater results.
• GI side effects were common (nausea, vomiting, diarrhea) but generally consistent with the GLP-1 class.

Current status: Phase 3 trials (ATTAIN program) are underway across multiple indications. Eli Lilly is also studying it for type 2 diabetes.

Bottom line: Even if orforglipron produces slightly less weight loss than injectable options, the convenience of a daily pill could be transformational for patients who refuse or cannot tolerate injections. That is a massive market. No needle, no cold chain storage, no reconstitution.

CagriSema (Novo Nordisk) -- semaglutide + amylin analog

CagriSema combines two compounds in a single injection: semaglutide (the active ingredient in Wegovy/Ozempic) and cagrilintide, a long-acting amylin analog.

The data so far:

• Phase 2 trial data presented at medical conferences showed approximately 15.6% weight loss at 32 weeks.
• The REDEFINE Phase 3 program reported that CagriSema achieved approximately 22.7% weight loss at 68 weeks, exceeding semaglutide alone (REDEFINE 1 topline results, Novo Nordisk press release, 2023).
• The amylin pathway adds satiety through a mechanism independent of GLP-1, potentially producing additive weight loss.

Current status: Phase 3 (REDEFINE program) is in progress. Novo Nordisk has indicated they plan to file for FDA approval, with a potential timeline of 2026-2027.

Bottom line: CagriSema is Novo Nordisk's answer to tirzepatide. The combination approach is logical -- two different satiety pathways should produce more weight loss than one. The Phase 3 data will determine whether the improvement over semaglutide alone justifies the added complexity.

For a broader comparison of all pipeline compounds, see our overview of new weight loss peptides in 2026.

---

FDA regulatory landscape for peptides in 2026

The regulatory environment for peptides has shifted dramatically in the past two years. Understanding the current rules is essential for anyone researching peptide options.

The three regulatory tiers

Peptides exist in three distinct legal categories. Each carries different quality standards, availability, and legal risk:

1. FDA-approved peptides -- Completed the full approval process. Manufactured under cGMP. Available by prescription. Examples: semaglutide (Wegovy/Ozempic), tirzepatide (Zepbound/Mounjaro).

2. Compounded peptides -- Made by compounding pharmacies under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Legally available by prescription when a patient-specific need exists (shortage, allergy to an ingredient, need for a different dosage form). Quality varies by pharmacy.

3. Research-only peptides -- Sold labeled "for research use only" or "not for human consumption." These exist in a legal gray area. Many people purchase them for personal use, but that use is not sanctioned by the FDA.

Compounding pharmacy crackdowns (2024-2026)

The biggest regulatory story in the peptide space has been the FDA's evolving stance on compounded versions of FDA-approved drugs, particularly semaglutide and tirzepatide.

When brand-name GLP-1 medications were in shortage, compounding pharmacies could legally produce copies under FDA shortage rules. As manufacturers have worked to resolve supply issues, the FDA has moved to restrict compounding:

• In late 2024, the FDA removed semaglutide from the drug shortage list, which triggered legal battles with compounding pharmacies.
• Multiple lawsuits have been filed challenging the FDA's shortage determinations and the restrictions on compounding.
• Several states have introduced their own legislation regarding peptide compounding access.

The situation remains fluid. For the latest regulatory developments, see our FDA peptide regulations 2026 article, which we update as significant changes occur.

What "research use only" actually means

"Research use only" (RUO) is a regulatory classification, not a consumer-protection loophole. Compounds sold under this label are intended for laboratory research, not human consumption. They are not manufactured under the same quality controls as pharmaceutical drugs.

When individuals purchase RUO peptides for personal use, they are operating in a legal gray area. The FDA has not broadly enforced against individual purchasers, but it has taken action against suppliers making therapeutic claims about RUO products.

For a deeper dive into the regulatory categories and their implications, see our full regulatory guide.

---

How to read a peptide study

This is arguably the most important section of this guide. If you can evaluate research quality yourself, you will never be misled by a headline again.

Study design hierarchy

Not all studies carry the same weight. Here is the evidence hierarchy from strongest to weakest:

1. Systematic reviews and meta-analyses -- Pool data from multiple trials. The most comprehensive form of evidence. A meta-analysis of GLP-1 trials across 10,000+ participants tells you far more than any single study.

2. Randomized controlled trials (RCTs) -- The gold standard for individual studies. Participants are randomly assigned to receive the drug or a placebo (or active comparator). Randomization eliminates most sources of bias.

3. Cohort studies -- Follow a group of people over time but without randomization. Observational, not experimental. More prone to confounding variables.

4. Case-control studies -- Compare people who have an outcome with those who do not, looking backward for exposures. Useful for generating hypotheses, not for proving causation.

5. Case reports and case series -- Descriptions of individual patients or small groups. Can identify new phenomena but cannot establish whether a treatment works.

6. Expert opinion -- Professional judgment without systematic evidence review. Valuable for clinical context but lowest on the evidence hierarchy.

7. Anecdotal reports -- Personal stories on Reddit, forums, or social media. Can point to interesting patterns but are subject to placebo effects, survivorship bias, and reporting bias.

When someone on a forum says "I lost 30 pounds on [peptide]," that is Level 7 evidence. When a Phase 3 RCT with 2,000 participants shows 15% average weight loss, that is Level 2. The difference matters enormously.

Key metrics to evaluate

When you read a peptide study, focus on these elements:

Sample size. How many people were in the trial? A study with 30 participants can suggest a signal but cannot confirm it. Phase 3 trials with 1,000+ participants provide much more reliable data. As a rough guide: under 50 participants = very preliminary; 100-500 = meaningful signal; 1,000+ = robust evidence.

Study duration. Weight loss compounds need long-term data. A 12-week study might show initial effects, but most weight loss medications need 6-12+ months to show their full effect. The STEP 1 semaglutide trial ran 68 weeks (PMID: 33567185). Short trials can overstate or understate real-world outcomes.

Primary endpoint. What was the study actually measuring? "Percentage of body weight lost" is a common endpoint, but studies also measure waist circumference, metabolic markers (HbA1c, triglycerides), liver fat, or other outcomes. Make sure the claim matches what the study actually measured.

Placebo control. Was there a placebo group? If not, you cannot separate the drug's effect from placebo response, lifestyle changes, or regression to the mean. The placebo group in STEP 1 lost 2.4% of body weight -- meaning roughly 2 percentage points of any participant's weight loss was not from the drug.

Statistical significance (p-values). A p-value below 0.05 is the conventional threshold for statistical significance, meaning there is less than a 5% probability the result occurred by chance. But p-values are widely misunderstood. A p-value of 0.04 does not mean the treatment "works." It means the observed difference is unlikely to be random noise. Clinical significance (is the effect large enough to matter?) and statistical significance are different questions.

Confidence intervals. These tell you the range within which the true effect likely falls. "15% weight loss (95% CI: 13.5-16.5)" is much more informative than "15% weight loss" alone. Narrow confidence intervals indicate more precise estimates. Wide intervals suggest more uncertainty.

Funding source. Who paid for the study? Industry-funded studies are not automatically biased, but they warrant additional scrutiny. Look for independent replication of industry-funded findings.

Red flags in study reporting

Watch for these warning signs:

• Cherry-picked endpoints. The study measured 10 things but only reports the 2 that looked good. Look for pre-registered primary endpoints on ClinicalTrials.gov.
• Per-protocol vs. intention-to-treat analysis. Per-protocol analysis excludes dropouts, which inflates results. Intention-to-treat includes everyone who started the trial, providing a more realistic picture.
• Conference abstracts without full publication. Abstracts presented at medical conferences are preliminary. The full peer-reviewed publication may tell a different story. Wait for the paper.
• Relative vs. absolute risk reduction. "50% reduction in X" sounds dramatic, but if the baseline risk was 2%, the absolute reduction is only 1 percentage point. Always look for absolute numbers.
• Animal-only data marketed as human-relevant. BPC-157 is a prime example -- extensive animal data but almost no published human clinical trials. Animal results do not reliably predict human outcomes.

---

Where to find reliable peptide research

Not all sources are equal. Here is where to look -- and where to be cautious.

Primary sources (highest reliability)

PubMed (pubmed.ncbi.nlm.nih.gov) The National Library of Medicine's database of biomedical literature. If a study has a PMID (PubMed ID), it has been indexed in this database. Most indexed studies have undergone peer review. This is the single most important resource for evaluating peptide research claims.

How to use it: Search by compound name (e.g., "retatrutide obesity"), filter by study type ("Clinical Trial," "Randomized Controlled Trial," "Meta-Analysis"), and sort by date for the latest findings.

ClinicalTrials.gov The U.S. government registry of clinical studies. Every legitimate clinical trial should be registered here before it begins. You can search by compound, condition, sponsor, and status. This tells you what trials are currently running, what they are measuring, and when results are expected.

How to use it: Search "retatrutide" to see every registered trial, its phase, enrollment, locations, and expected completion date. Bookmark compounds you are tracking.

FDA.gov For approved drugs, the FDA website provides prescribing information, approval history, safety alerts, and advisory committee documents. When the FDA holds an advisory committee meeting for a new drug, the briefing documents are publicly available and often contain the most detailed efficacy and safety data outside the published trials themselves.

Secondary sources (useful with verification)

Journal articles in indexed publications. The New England Journal of Medicine, The Lancet, JAMA, and Obesity are among the top-tier journals for weight loss peptide research. Articles in these journals have undergone rigorous peer review.

Medical news sites. Sites like STAT News, Medscape, and Endocrine Today report on new research but are secondary sources. They summarize studies, which means interpretation has been layered on top of the data. Always trace back to the original study.

Preprint servers (medRxiv, bioRxiv). Preprints are research papers that have not yet been peer-reviewed. They offer early access to findings but carry higher risk of errors, bias, or conclusions that do not survive the review process. Treat preprint findings as preliminary.

Sources to approach with caution

Social media and forums. Reddit communities (r/Peptides, r/Semaglutide), Twitter/X, and TikTok are where most people first hear about peptides. These platforms contain valuable real-world experiences, but they are subject to survivorship bias (people who had bad experiences stop posting), placebo effects, and outright misinformation. Use them to identify questions worth researching, not as evidence.

Vendor websites and marketing materials. Companies selling peptides have a financial incentive to present their products favorably. Claims on vendor sites should always be verified against primary sources. "Supported by clinical research" on a vendor page means nothing without a specific citation you can check.

Influencer content. Some influencers have genuine expertise. Many do not. Evaluate influencer claims the same way you would evaluate any other claim: trace it back to the data.

---

Red flags in peptide research claims

When you encounter a peptide claim online, run it through this checklist:

1. No citation provided. If someone claims "studies show" but does not link to or name the study, treat the claim as unverified.

2. Animal data presented as human evidence. "This peptide reduced inflammation by 60%" may be true -- in rats. The gap between animal and human outcomes is enormous.

3. Single study treated as definitive. One study, even a good one, is a data point. It takes multiple studies with consistent results to build strong evidence.

4. Absolute language. "Cures," "eliminates," "guarantees" -- these words do not belong in honest science communication. Real researchers use hedged language ("may," "suggests," "associated with") because that is what the data supports.

5. Conflicts of interest undisclosed. Is the person making the claim selling the product? Do they have an affiliate relationship? Financial incentives do not automatically invalidate claims, but they require additional scrutiny.

6. Results that seem too good. If a compound allegedly solves everything with zero downsides, skepticism is warranted. Every effective drug has side effects. Every treatment has non-responders.

7. Mechanism claims without evidence. "This peptide works by activating X pathway" may be true in theory but unproven in practice. Proposed mechanisms are hypotheses until validated in human studies.

---

The evidence hierarchy: putting it all together

Here is a practical framework for weighting peptide evidence. We use this hierarchy in all our analysis on this site:

Evidence Level	Example	Weight
Systematic review / meta-analysis	Cochrane review of GLP-1 agonists	Highest
Phase 3 RCT (1,000+ participants)	STEP 1 (semaglutide), SURMOUNT-1 (tirzepatide)	Very high
Phase 2 RCT (100-500 participants)	Retatrutide Phase 2, survodutide Phase 2	High (but needs confirmation)
Phase 1 / small clinical study	Early-stage dosing studies	Moderate
Cohort / observational study	Real-world data from electronic health records	Moderate (no randomization)
Animal / in vitro study	BPC-157 rodent studies	Low (not human data)
Case report / case series	Published reports of individual patients	Low
Anecdotal / forum report	Reddit, TikTok, personal testimonials	Very low

This does not mean anecdotal evidence is worthless. Forum reports can identify patterns worth studying. But they should never be the basis for health decisions on their own.

---

Research-only vs. FDA-approved compounds

This distinction is critical and widely misunderstood.

FDA-approved compounds have completed the full regulatory process. Their safety and efficacy have been demonstrated in large clinical trials. Manufacturing is tightly controlled. Side effect profiles are well-documented. Examples: semaglutide, tirzepatide, liraglutide, tesamorelin.

Research-only compounds have not completed this process. They may have promising preclinical data or early clinical data, but they have not been evaluated by the FDA for safety and efficacy in their intended use. Manufacturing quality is not standardized. Examples: BPC-157, TB-500, MOTS-c, GHK-Cu, and any compound sold as "for research use only."

Some research-only compounds have extensive preclinical literature. BPC-157, for instance, has hundreds of published animal studies. But it has almost no published human clinical trial data. That does not mean it is ineffective -- it means we do not have the same level of evidence that we have for FDA-approved drugs.

The practical implication: when considering any peptide, know which category it falls into. FDA-approved compounds carry lower uncertainty. Research-only compounds carry higher uncertainty, both in terms of efficacy and in terms of manufacturing quality and purity.

---

Notable recent studies (2024-2026)

These studies represent some of the most significant peptide research published recently. We have selected them for their impact on the weight loss peptide landscape.

1. Retatrutide Phase 2 obesity trial

PMID: 37351564 -- The New England Journal of Medicine, 2023

Triple agonist (GLP-1/GIP/glucagon). 338 participants, 48 weeks. Highest dose group achieved 24.2% mean weight loss. Established retatrutide as the most potent weight loss compound in clinical development. Full analysis.

2. Semaglutide STEP 1 trial

PMID: 33567185 -- The New England Journal of Medicine, 2021

The pivotal trial that led to Wegovy's approval. 1,961 participants, 68 weeks. 2.4 mg semaglutide produced 14.9% mean weight loss vs. 2.4% for placebo. This remains the foundational dataset for semaglutide in obesity.

3. Tirzepatide SURMOUNT-1 trial

PMID: 35658024 -- The New England Journal of Medicine, 2022

The Phase 3 trial that established tirzepatide as the most effective FDA-approved weight loss medication. 2,539 participants, 72 weeks. Highest dose (15 mg) produced 20.9% mean weight loss.

4. Tirzepatide vs. semaglutide head-to-head (SURMOUNT-5)

PMID: 37840095 -- The New England Journal of Medicine, 2023

The first direct comparison trial. Tirzepatide produced significantly greater weight loss than semaglutide (approximately 20.2% vs. 13.7% at 72 weeks). This confirmed what cross-trial comparisons had suggested.

5. Survodutide Phase 2 obesity trial

PMID: 38587239 -- The Lancet, 2024

GLP-1/glucagon dual agonist. 387 participants, 46 weeks. Approximately 18.7% weight loss at the highest dose. Notable for its effects on liver fat, positioning survodutide as a potential treatment for both obesity and MASLD.

6. Orforglipron Phase 2 trial

PMID: 37351563 -- The New England Journal of Medicine, 2023

Oral GLP-1 receptor agonist (non-peptide small molecule). 272 participants, 36 weeks. Approximately 14.7% weight loss. Significant because it demonstrates that injectable delivery may not be required for meaningful GLP-1-based weight loss.

7. Semaglutide SELECT cardiovascular trial

PMID: 37952131 -- The New England Journal of Medicine, 2023

17,604 participants with established cardiovascular disease and overweight/obesity (without diabetes). Semaglutide reduced major adverse cardiovascular events by 20% compared to placebo. This was the first trial to demonstrate that a weight loss medication reduces heart attacks and strokes, expanding semaglutide's clinical significance far beyond weight management.

8. Tirzepatide SURMOUNT-MMO (ongoing)

ClinicalTrials.gov: NCT05556512

A massive outcomes trial (approximately 15,000 participants) testing whether tirzepatide reduces heart attacks, strokes, and cardiovascular death in people with obesity. Results are expected in the coming years and could further establish the cardiovascular benefits of the incretin class.

---

Frequently Asked Questions

How long does it take for a peptide to go from Phase 2 to FDA approval?

Typically 4-7 years. Phase 3 trials alone take 2-4 years to complete. After that, the company compiles a New Drug Application (NDA), which the FDA reviews over 10-12 months. Add in manufacturing scale-up, advisory committee meetings, and potential requests for additional data, and the full timeline from first Phase 2 results to pharmacy availability is substantial. For the retatrutide timeline specifically, see our retatrutide FDA approval timeline.

Can I trust peptide research that has not been peer-reviewed?

Approach it with caution. Peer review is not perfect -- it does not catch every error -- but it provides a meaningful quality filter. Preprints, conference abstracts, and press releases from pharmaceutical companies are useful for staying current, but they should not be treated with the same confidence as peer-reviewed publications. When making health decisions, prioritize peer-reviewed data.

What is the difference between a pre-print and a published study?

A preprint is a research manuscript that has been posted publicly before formal peer review. It has not been evaluated by independent experts in the field. A published study has undergone peer review, where other scientists assess the methodology, analysis, and conclusions before the journal agrees to publish it. Preprints are faster to access but carry higher uncertainty.

Why do peptide results in animals often not translate to humans?

Several reasons. Animal metabolism differs from human metabolism. Dosing that works in a 300-gram rat does not scale linearly to a 90-kg human. Rodents have different receptor densities, gut microbiomes, hormonal profiles, and lifespans. Some compounds that cross the blood-brain barrier in mice do not in humans. The translation gap is why clinical trials exist -- animal data generates hypotheses that human trials test.

How do I look up a specific peptide's clinical trial status?

Go to ClinicalTrials.gov and search by compound name (e.g., "retatrutide" or "LY3437943" for the research code). Filter by status ("Recruiting," "Active, not recruiting," "Completed") to see where things stand. Each listing includes the study phase, enrollment, primary endpoints, sponsor, and estimated completion date.

Are compounded peptides as effective as brand-name versions?

Compounded peptides contain the same active ingredient, but manufacturing processes and quality controls vary between compounding pharmacies. Some 503B outsourcing facilities operate under rigorous standards. Others do not. The FDA has identified quality issues in some compounded GLP-1 products, including incorrect concentrations and contamination. If using a compounded peptide, the pharmacy's track record and testing practices matter significantly.

What does "research-only" mean when a vendor sells a peptide?

It means the compound has not been approved by the FDA for human use. It is sold under the legal framework of being intended for laboratory research purposes. Vendors use this label to comply with regulations while selling to a market that largely includes individuals planning personal use. The quality, purity, and dosing accuracy of research-only peptides are not guaranteed by any regulatory body.

How can I tell if a peptide study is industry-funded?

Check the "Funding" or "Conflicts of Interest" section of the published paper -- every reputable journal requires this disclosure. On ClinicalTrials.gov, the "Sponsor" field shows who is running and funding the trial. Industry funding does not automatically invalidate results, but it is a factor worth noting, particularly when independent replication has not yet occurred.

---

Sources

1. Retatrutide Phase 2 obesity trial -- The New England Journal of Medicine, 2023
2. Semaglutide STEP 1 trial -- The New England Journal of Medicine, 2021
3. Tirzepatide SURMOUNT-1 trial -- The New England Journal of Medicine, 2022
4. Tirzepatide vs. Semaglutide (SURMOUNT-5) -- The New England Journal of Medicine, 2023
5. Survodutide Phase 2 trial -- The Lancet, 2024
6. Orforglipron Phase 2 trial -- The New England Journal of Medicine, 2023
7. Semaglutide SELECT cardiovascular trial -- The New England Journal of Medicine, 2023
8. Tirzepatide SURMOUNT-MMO -- ClinicalTrials.gov

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. This site presents published research and evidence-based analysis -- not medical recommendations.